GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Inventage Lab Inc (XKRX:389470) » Definitions » EBITDA Margin %

Inventage Lab (XKRX:389470) EBITDA Margin % : 98.63% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Inventage Lab EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Inventage Lab's EBITDA for the three months ended in Mar. 2024 was ₩95.6 Mil. Inventage Lab's Revenue for the three months ended in Mar. 2024 was ₩96.9 Mil. Therefore, Inventage Lab's EBITDA margin for the quarter that ended in Mar. 2024 was 98.63%.


Inventage Lab EBITDA Margin % Historical Data

The historical data trend for Inventage Lab's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventage Lab EBITDA Margin % Chart

Inventage Lab Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- -2,187.06 -393.00 -216.66 -3,570.66

Inventage Lab Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,752.34 -5,118.30 -5,833.29 788.09 98.63

Competitive Comparison of Inventage Lab's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Inventage Lab's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inventage Lab's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Inventage Lab's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Inventage Lab's EBITDA Margin % falls into.



Inventage Lab EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Inventage Lab's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-23500.362/658.152
=-3,570.66 %

Inventage Lab's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=95.601/96.928
=98.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inventage Lab  (XKRX:389470) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Inventage Lab EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Inventage Lab's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Inventage Lab (XKRX:389470) Business Description

Traded in Other Exchanges
N/A
Address
24, Dunchon-daero 388 beon-gil, 612, Woolim Lions Valley 3, Jungwon-gu, Gyeonggi-do, Seongnam-si, KOR, 13403
Inventage Lab Inc operates medical technology development businesses. It engages in the development of an innovative Drug Delivery System (DDS). It has developed Laminar FluiDigm, a microfluidics-based novel platform technology that builds the foundation for IVL- DrugFluidic and IVL-GeneFluidic, which are specific platform technologies used for developing and manufacturing long-acting injectables and gene-delivery therapeutics.

Inventage Lab (XKRX:389470) Headlines

No Headlines